Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its ...

U.S. drugmaker Merck said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

The 470,000-square-foot facility will support the launch and commercial production of next-generation biologics and therapies ...

According to Merck, the total investment is now expected to be over $1 billion, with 500 full-time jobs and 4,000 ...

Merck is particularly exposed to the tariff threat, as much of its production of Keytruda takes place at facilities in ...

Merck announced on Tuesday that it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster ...

Located at Chestnut Run Innovation & Science Park, the Merck Wilmington Biotech project will comprise laboratory, ...

It will build a Wilmington, Delaware facility dedicated to making its cancer drug, Keytruda, for U.S. patients.

The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.

Merck & Co (MSD) has begun construction on a $1bn biologics centre of excellence, Merck Wilmington Biotech, in Delaware, US.

Merck estimates the project will create more than 500 full-time roles and about 4,000 construction jobs. CEO of Main Line ...